| Bioactivity | Bafisontamab (EMB-01) is a bispecific antibody targeting EGFR and cMET with antitumor activity[1]. |
| In Vivo | Bafisontamab (EMB-01) 在 PDX 和 CDX 肿瘤模型中诱导的抗肿瘤活性明显强于抗 EGFR 单抗或抗 cMet 单抗。Bafisontamab 在抗 EGFR mAb 耐药肿瘤模型中表现出显著的抗肿瘤活性[1]。 |
| Name | Bafisontamab |
| CAS | 2437210-79-0 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ren F, et al. EMB-01: An innovative bispecific antibody targeting EGFR and cMet on tumor cells mediates a novel mechanism to improve anti-tumor efficacy. Cancer Research, 2020, 80(16_Supplement): 528-528. |